Pfizer (China)

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.5K citations · Full text

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Mark G. Kris, D. Ross Camidge, Giuseppe Giaccone et al. · Annals of Oncology · 2015 · 323 citations · Full text

Her2 Aberrations, Lung Cancers, Oncology +10

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

D L Boyle, K. Soma, J Hodge et al. · Annals of the Rheumatic Diseases · 2014 · 287 citations · Full text

Effects of Varenicline on Smoking Cessation in Patients With Mild to Moderate COPD

Donald P. Tashkin, Stephen I. Rennard, J. Taylor Hays et al. · CHEST Journal · 2010 · 210 citations

Tobacco Control, Pulmonary Care, Smoking Related Lung Disease +5